Eclipse Surgical
This article was originally published in The Gray Sheet
Executive Summary
Brightened image through name change to CardioGenesis is foreseen by the transmyocardial revascularization system developer. Announced June 18, the change reflects plans to offer a broader range of products for cardiovascular disease, possibly including delivery systems for growth factor compounds. The new appellation is taken from a March 1999 acquisition by the same name. The firm's stock symbol also changes June 21 to "CGCP." The Sunnyvale, California company simultaneously announces plans to move its headquarters from Silicone Valley to Foothill Ranch, California by August to cut expenses. A PMA supplement for the firm's percutaneous myocardial revascularization system is scheduled for FDA panel review July 9...
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.